Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.62 |
| ▸ | PTPRC | P08575 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 4/20 | 0.44 |
| ▸ | NQO1 | P15559 | 1/20 | 0.44 |
| ▸ | POR | P16435 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | EED | O75530 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27927489 | 0.98 | DNMT1 (0.60) | DNMT1PTPRCCES1NQO1POR | |
| SCHEMBL17767261 | 0.87 | DNMT1 (0.53) | DNMT1PTPRCCES1NQO1POR | |
| SCHEMBL30570716 | 0.87 | DNMT1 (0.53) | DNMT1PTPRCCES1NQO1POR | |
| SCHEMBL19230419 | 0.80 | DNMT1 (0.83) | DNMT1CES1ALDH1A1MAPTRAB9A | |
| SCHEMBL16144677 | 0.78 | DNMT1 (0.80) | DNMT1CES1ALDH1A1MAPTRAB9A | |
| SCHEMBL1055754 | 0.77 | DNMT1 (1.00) | DNMT1PTPRCCES1ALDH1A1MAPT | |
| SCHEMBL31174009 | 0.77 | DNMT1 (1.00) | DNMT1PTPRCCES1ALDH1A1MAPT | |
| SCHEMBL16152313 | 0.75 | EED (0.69) | DNMT1CES1NQO1PORALDH1A1 | |
| SCHEMBL7122517 | 0.74 | DNMT1 (0.73) | DNMT1CES1ALDH1A1MAPTRAB9A | |
| SCHEMBL19230420 | 0.74 | DNMT1 (0.73) | DNMT1PTPRCCES1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160022625-A1 | TASHINONES AND THEIR DERIVATIVES: NOVEL EXCELLENT DRUGS FOR ALZHEIMER DISEASE | THE UNIVERSITY OF AKRON | 2016-01-28 | — | — | US | disclosed |
| US-20160022625-A1 | TASHINONES AND THEIR DERIVATIVES: NOVEL EXCELLENT DRUGS FOR ALZHEIMER DISEASE | THE UNIVERSITY OF AKRON | 2016-01-28 | — | — | US | disclosed |
| WO-2014138357-A1 | NOVEL TASHINONE DRUGS FOR ALZHEIMER DISEASE | THE UNIVERSITY OF AKRON (US) | 2014-09-12 | — | — | WO | disclosed |
| CN-102499913-B | Preparation method for refined and purified paeonol preparation | GUANGXI YIKANG PHARMACEUTICAL CO LTD | 2013-07-10 | — | — | CN | disclosed |
| CN-103083332-A | Application of tanshinone IIA to preparing drugs or cosmetics for inhibiting propionibacterium acnes | SHANGHAI LAIBO BIO CHEMICAL CO LTD | 2013-05-08 | — | — | CN | disclosed |
| CN-103083333-A | Application of tanshinone IIA in preparation of medicine for treating malassezia induced skin disease | SHANGHAI LAIBO BIO CHEMICAL CO LTD | 2013-05-08 | — | — | CN | disclosed |
| US-8404869-B2 | Phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome | MAZENCE INC. (KR) | 2013-03-26 | — | — | US | disclosed |
| CN-102020521-A | Preparation mode and application of deuterium substituted Chinese herbal monomer | CHEN SONGYUAN | 2011-04-20 | — | — | CN | disclosed |
| CN-101766551-A | Drug toothpaste for treating oral diseases and preparation method thereof | TIANJIN TIENS GROUP CO LTD | 2010-07-07 | — | — | CN | disclosed |
| US-20100137422-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | YUNGJIN PHARM. CO., LTD. (KR) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022625-A1 | TASHINONES AND THEIR DERIVATIVES: NOVEL EXCELLENT DRUGS FOR ALZHEIMER DISEASE | APP, HTT, PSEN1 | DNMT1 4821/4885PTPRC 4519/4885CES1 3339/4885 |
| US-20100137422-A1 | NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME | CYP27A1, CYP46A1, PCSK9 | DNMT1 4516/4885PTPRC 4052/4885CES1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.